Newly Approved Drug for CLL: Acalabrutinib (Calquence)
Published on November 21, 2019
The FDA has approved a new chronic lymphocytic leukemia (CLL) drug: acalabrutinib (Calquence). Want to learn more about this newly approved drug? Attend our daily wraps from ASH 2019 and our live CLL Ask the Expert coming up early December. Register at https://patientpower.info/events/
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
What a wonderful time we had! We were excited like fans at a rock concert, but our rock stars were the medical experts.
